IL1B and cryopyrin-associated periodic syndrome: Further studies of both anakinra and canakinumab in larger pediatric serial studies are needed, including careful analysis of the pharmacokinetics in children younger than 4 years of age and long-term follow-up, in order to achieve a rational approach with IL-1 blockers for the broad phenotypic spectrum of CAPS in both children and adults.